AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024
AngioDynamics (NASDAQ: ANGO), a medical technology company specializing in vascular health and cancer treatment, has announced its plans to release fiscal 2025 first quarter financial results on October 3, 2024, before the market opens.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international).
This conference call will also be webcast and can be accessed from the “Investors” section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
A recording of the call will also be available, until Thursday, October 10, 2024 at 11:59 pm ET. To hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13748896.
About AngioDynamics, Inc.
AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life.
The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240919022291/en/
Investors:
AngioDynamics, Inc.
Stephen Trowbridge, Executive Vice President & CFO
(518) 795-1408
Source: AngioDynamics, Inc.